# A Study to Evaluate Luspatercept Treatment Patterns and Outcomes in Erythropoiesis-Stimulating Agents-Naïve Patients With Lower-Risk Myelodysplastic Syndromes in the United States

> **NCT06851065** · — · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 418 (actual)

## Conditions studied

- Myelodysplastic Syndromes

## Interventions

- **DRUG:** Luspatercept
- **DRUG:** Erythropoiesis-stimulating agents

## Key facts

- **NCT ID:** NCT06851065
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2024-08-22
- **Primary completion:** 2025-03-10
- **Final completion:** 2025-03-10
- **Target enrollment:** 418 (ACTUAL)
- **Last updated:** 2026-02-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06851065

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06851065, "A Study to Evaluate Luspatercept Treatment Patterns and Outcomes in Erythropoiesis-Stimulating Agents-Naïve Patients With Lower-Risk Myelodysplastic Syndromes in the United States". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06851065. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*